Analysts think CAPR stock price could increase by 172%
Aug 08, 2025, 11:25 AM
-16.42%
What does CAPR do
Capricor Therapeutics, based in Beverly Hills, develops biological therapies for serious medical conditions, focusing on CAP-1002 for Duchenne muscular dystrophy in Phase 3 trials. The company also utilizes exosome technology for various therapeutic applications.
12 analysts think CAPR stock price will increase by 171.75%. The current median analyst target is $21.93 compared to a current stock price of $8.07. The lowest analysts target is $12.12 and the highest analyst target is $30.45.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
